摘要
中国肝细胞癌(HCC)发病及死亡人数约占全球50%。HCC早期诊断率低及术后复发率高是我国HCC患者5年生存率欠佳的两大原因。当前存在筛查技术性能及依从性较低、缺乏有效预测术后复发标志物等问题。液体活检等新型分子标志物因其简便、精准等特点,有望成为传统筛查预警方法的有益补充,实现HCC的早期发现及精准治疗。现就液体活检在HCC早筛及治疗后复发预测中的临床转化应用进行论述,并对未来研究进行展望。
The incidence and mortality of HCC in China account for approximately 50%of all cases worldwide.Low early diagnosis rate and high postoperative recurrence rate are two major causes for poor 5-year survival rate of HCC patients in China.At present,multiple problems such as low performance and compliance of screening technology and lack of effective markers for predicting postoperative recurrence,remain to be resolved.Due to the simplicity and accuracy,new molecular markers,such as liquid biopsy,are expected to serve as supplementary tools to traditional screening and early warning approaches,thereby realizing early detection and accurate treatment of HCC.In this article,research progress upon the clinical application of liquid biopsy in early screening and prediction of postoperative recurrence of HCC was reviewed,and prospects the future research.
作者
郝新
邓淑云
王坤远
陈磊
侯金林
魏卫卫
陈锦章
Hao Xin;Deng Shuyun;Wang Kunyuan;Chen Lei;Hou Jinlin;Wei Weiwei;Chen Jinzhang(Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Guangdong Provincial Institute of Liver Diseases,Guangzhou 510515,China;National Center for liver Cancer/Eastern Hepatobiliary Surgery Hospital,Navy Medical University,Shanghai 200433,China;Medical Affairs Department,Berry Oncology Clinical Laboratory,Fuzhou 350200,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2022年第8期814-819,共6页
Chinese Journal of Hepatology
关键词
肝细胞癌
早期筛查
复发
液体活检
Hepatocellular carcinoma
Early screening
Recurrence
Liquid biopsy
